Amicus Therapeutics, Inc. (NASDAQ:FOLD) stock is presently standing at about $9.96 and lots of equity research firms seem to have a target price set on the stock. The median one-year price target of 6 analysts covering the company is $12.25, which suggests the stock could still rise over 19 percent. The highest analyst price target is $18.00, which implies a rally of 19 percent. And a quick view of analyst notes show that 3 are rating the stock a buy while 3 rate FOLD a strong buy. There are 1 equity research firms advocating a Hold and 0 consider it Sell.
Robert W. Baird analysts provided their view on Amicus Therapeutics, Inc. (NASDAQ:FOLD) recently. The rating firm issued a Outperform rating to this company in a research note released on Jan 24, 2017. BofA/Merrill analysts disclosed their opinion on Amicus Therapeutics, Inc. (NASDAQ:FOLD) recently. The rating firm gave a Buy rating to this stock in a research note published on May 18, 2016. According to a research note disclosed on Sep 16, 2015, analysts at Chardan Capital Markets have lowered their rating on these shares from Buy to Neutral.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Transactions Roundup
Several insiders were part of recent insider activity for the stock. Its Chief Medical Officer Barth Jay Sold 64,184 company shares for 300,000, in a transaction on Jun 19. Following the transaction, the Chief Medical Officer is left with a stake of 30,000 shares, currently valued at $298,800. Meanwhile, Chief Science Officer Do Hung sold 474,438 shares worth $239,312, through a transaction dated May 19. Following the completion of the transaction, the insider is left with a stake of 29,914 shares, amounting $297,943. FOLD Chief Science Officer Do Hung also sold 504,352 shares, at a stock price of $8.00. This transaction occurred on May 15 totals $239,312. After this transaction, the insider’s stake stands at 29,914 shares, with a market value of $297,943.
Executives hold 1.32 percent of the stock. FMR LLC is one of the biggest insider owners in Amicus Therapeutics, Inc. (NASDAQ:FOLD), according to U.S. Securities and Exchange Commission (SEC) filings. The insider owns 20,732,355 shares which have current market value of around $206,494,256.PERCEPTIVE ADVISORS LLC is another major inside shareholder in the company. The insider owns 17,296,672 shares as of 03/31/2017, currently worth $172,274,853. BLACKROCK INC. is ranked as third insider holder of the stock. This insider holds 11,967,596 shares with a market value around $119,197,256 as of recent close.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Earnings Outlook
In Amicus Therapeutics, Inc. (NASDAQ:FOLD)’s latest quarter, EPS moved to $-0.39 from $-0.42 in preceding quarter and revenues reached at $4.17M compared to $2.83M. Analysts had expected Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post net income of about $-0.36 per share on $4.16M in revenue. Looking ahead, analysts on average predict that earnings for the current quarter would come in the range of $-0.39 to $-0.33. That is compared with the $-0.4 in EPS it reported during the same period a year ago.